Vivos Therapeutics, Inc. (VVOS) · Oct 19, 2026 · Acquisition
$12M acquisition — 11% of SOD plus 50% of the test for $12M in preferred stock
Vivos completed its SOD acquisition with no cash paid, adding a potential diagnostic growth channel—but dilution, validation and execution risks remain.
Vivos is in the middle of a business-model pivot: away from relying mainly on dentist enrollment and toward sleep-center alliances, acquired clinical operations and broader OSA testing and treatment services. Recent disclosures also show a sharp cost-reduction effort and continued pressure to restore Nasdaq equity compliance.
The transaction is now closed, but it is primarily an option on a new business line. Vivos received an 11% fully diluted stake in SOD and a 50% co-ownership interest in its pseudohypoxia early-warning test in exchange for preferred stock, with no cash leaving the company.
| Item | Filing figure / term |
|---|---|
| SOD equity acquired | 11% fully diluted |
| Test IP acquired | 50% co-ownership |
| Consideration | $12 million stated value of Series C Preferred |
| Cash paid | None |
| Potential conversion at $0.15 | Up to 80 million common shares, subject to caps |
| Pro forma stockholders’ equity | Approximately $6.6 million |
| Nasdaq minimum requirement | $2.5 million |
The upside is still several steps away from revenue. Management points to access to more than 325,000 AHA patients across roughly 3,000 facilities and a potentially multi-million-dollar testing opportunity beginning in 2027, but those channels require new definitive agreements, clinical validation, regulatory progress and bankruptcy-court approval. The filing expressly says the release does not establish that the test predicts any condition. 〔0〕
The deal improves the listing-capital story, but not yet conclusively. Vivos estimates pro forma stockholders’ equity of about $6.6 million and expects the transaction to add more than $10 million, versus Nasdaq’s $2.5 million threshold. However, the accounting treatment still requires review by the auditor and Nasdaq, and compliance must be demonstrated again in a future periodic report.
The consideration creates a meaningful dilution overhang. The Series C Preferred converts at $0.15 per share and could convert into as many as 80 million common shares, although the 19.99% exchange cap applies until stockholder approval and a separate beneficial-ownership limit restricts individual conversions.
The closing is partly known rather than a fresh strategic surprise. The agreement was announced on October 14, 2026 and publicly described before this filing; the new information is that the transaction completed, the exact assignment and co-ownership mechanics are documented, and the potential Nasdaq-equity benefit is now reflected in updated pro forma information. The transaction therefore advances Vivos’s diversification plan, but its commercial value remains contingent rather than demonstrated.
Bottom line: This closes a strategically important expansion beyond sleep-apnea treatment and may help Vivos clear its equity hurdle, but it is not yet a proven revenue event. The immediate trade-off is optionality and balance-sheet support in exchange for execution risk and substantial potential dilution.
AHA agreements and bankruptcy-court approval
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!